Pharmacological therapies for obesity

Area of Science:

• Pharmacology
• Endocrinology
• Metabolic Diseases

Background:

• Obesity pharmacotherapy has historically faced challenges with limited effective agents and safety concerns, leading to withdrawals.
• Current FDA-approved obesity medications include phentermine, sibutramine (appetite suppressants, thermogenesis), and orlistat (fat absorption inhibitor).
• Other medications like bupropion, metformin, topiramate, and zonisamide are used off-label for weight management or to counteract medication-induced weight gain.

Purpose of the Study:

• To review the current landscape of pharmacological obesity treatment.
• To highlight emerging molecular targets and novel agents in development.
• To discuss the potential for combination therapies in managing complex weight regulation.

Main Methods:

• Literature review of current and investigational obesity pharmacotherapies.
• Analysis of physiological mechanisms underlying body weight regulation.
• Synthesis of information on FDA-approved and off-label medications.

Main Results:

• The field of obesity pharmacotherapy is undergoing significant transition.
• Over 150 novel anti-obesity agents targeting new molecular pathways are in active development.
• Existing drugs like phentermine, sibutramine, and orlistat have specific mechanisms of action.

Conclusions:

• The complexity of weight regulation suggests that combination therapies will be crucial for effective obesity treatment.
• Advancements in understanding physiological mechanisms are driving the development of new therapeutic agents.
• The emergence of novel medications will enable the creation of more effective combination treatment strategies for obesity.